RMD is seeing rising device demand, expanding international sales and strong liquidity, but macroeconomic pressures could ...
ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple ...
For my first rating of ResMed, I'm calling a buy, agreeing with today's consensus from Wall St. and more confident than the quant system, which said hold. Key upside factors are new business ...
Revenue: $1.35 billion, a 10% increase year-over-year. Gross Margin: 61.4%, an expansion of 230 basis points year-over-year. Free Cash Flow: $1.7 billion for fiscal year 2025. Net Income: Increased by ...
ResMed reported Q4 FY2025 revenue of $1.35 billion, representing a 10% increase compared to $1.22 billion in Q4 FY2024. This performance exceeded the previous quarter’s revenue of $1.3 billion ...
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Receives a Buy from Macquarie Nov. 3, 2025 at 6:35 p.m. ET on TipRanks.com ...
The ResMed Inc (ASX: RMD) share price is rising on Friday morning. At the time of writing, the sleep disorder treatment company's shares are up 2.5% to a record high of $43.47. This follows the ...
Shares of ResMed Inc. shed 8.33% to $236.18 Friday, on what proved to be an all-around dismal trading session for the stock ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback